The resistance to TKIs in CML is multifaceted, involving BCR-ABL kinase mutations and the BM microenvironment’s role in providing survival signals to residual leukemic cells [120,121,122,123]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.